Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations

被引：0
|
作者：
Zhang, Q. [1 ]
Ke, L. [1 ]
Huang, S. [2 ]
Yang, Y. [1 ]
He, T. [1 ]
Sun, H. [3 ]
Wu, Z. [1 ]
Zhang, X. [4 ]
Lv, W. [1 ]
Hu, J. [1 ]
Ye, J. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China
[3] Zhejiang Univ, Taizhou Hosp, Taizhou, Peoples R China
[4] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Aumolertinib; Adjuvant; Uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.07
引用
收藏
页码：S555 / S556
页数：2
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer
    Kawamura, Masafumi
    Eguchi, Keisuke
    Izumi, Yotaro
    Yamato, Yasushi
    Koike, Teruaki
    Sakaguchi, Hirozo
    Hada, Enjo
    Kobayashi, Koichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 495 - 501
  • [22] Adjuvant treatment of completely resected stage IB-IIIA non-small-cell lung cancer - a retrospective study with cisplatin or carboplatin and oral vinorelbine
    Engel-Riedel, W.
    Alten, N.
    Bachinger, A.
    Magnet, F. S.
    Ludwig, C.
    Stoelben, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S805 - S805
  • [23] Radiotherapy for patients with completely resected pathologic IIIA(N2) non-small-cell lung cancer: a retrospective analysis
    Zhu, Ying
    Fu, Lei
    Jing, Wang
    Kong, Li
    Yu, Jinming
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 10901 - 10908
  • [24] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
    Wu, Fang
    Liu, Xianling
    Ma, Jin-an
    Gao, Yawen
    Hu, Chunhong
    LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124
  • [25] Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
    Chen Shi
    Cong Zhang
    Zhiwen Fu
    Jinmei Liu
    Yuanfeng Zhou
    Bao Cheng
    Cong Wang
    Shijun Li
    Yu Zhang
    Acta Pharmaceutica Sinica B, 2023, (06) : 2613 - 2627
  • [26] Is adjuvant radiochemotherapy superior to postoperative radiotherapy alone in patients with completely resected stage II or IIIA non-small cell lung cancer?
    Baumann, M
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (04) : 220 - 221
  • [27] Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer - The Movsas article reviewed
    Wagner, H
    ONCOLOGY-NEW YORK, 2002, 16 (01): : 105 - 106
  • [28] Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
    Shi, Chen
    Zhang, Cong
    Fu, Zhiwen
    Liu, Jinmei
    Zhou, Yuanfeng
    Cheng, Bao
    Wang, Cong
    Li, Shijun
    Zhang, Yu
    ACTA PHARMACEUTICA SINICA B, 2023, 13 (06) : 2613 - 2627
  • [29] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [30] ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN IN PATIENTS WITH COMPLETELY RESECTED STAGE-I NON-SMALL-CELL LUNG-CANCER
    FELD, R
    RUBINSTEIN, L
    THOMAS, PA
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (04): : 299 - 306
12345